squalene and COVID-19

Evaluation of the effectiveness of microemulsion containing extracted squalene based on oilseeds for the treatment of COVID-19

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200927048848N2

Enrollment

Registered

2020-11-04

Start date

2020-10-31

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19 disease. covid-19 disease

Interventions

Intervention 1: Intervention group: main treatment plus injection of 20 mg squalene microemulsion every 8 hours for 6 days. Intervention 2: Control group: main treatment includes 150 mg chloroquine (e

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with Covid-19 who have been confirmed by CT scan The patient has been admitted to the Intensive Care Unit (ICU) due to severe or critical condition

Exclusion criteria

Exclusion criteria: Known history of myocardial ischemia and heart failure and advanced COPD No consent of the patient or with the drug injection. Any mental disability that prevents effective communication. Existence of any physical disability that prevents one from performing daily activities independently. (Physical disability leads to disability before COVID-19 disease)

Design outcomes

Primary

Measure	Time frame
Response to treatment criteria including respiratory rate, SPO2 in room air , presence or absence of fever for 2 days, oral tolerance, clinical judgment of the physician. Timepoint: Response to treatment will be evaluated daily, 24 hours after the first injection. Method of measurement: The number of breaths per minute will be counted by the evaluator, the blood oxygen level will be checked with a pulse oximeter, the fever will be measured sublingually using a mercury thermometer. Oral tolerance will also be recorded by evaluators.	—

Measure

Time frame

Response to treatment criteria including respiratory rate, SPO2 in room air , presence or absence of fever for 2 days, oral tolerance, clinical judgment of the physician. Timepoint: Response to treatment will be evaluated daily, 24 hours after the first injection. Method of measurement: The number of breaths per minute will be counted by the evaluator, the blood oxygen level will be checked with a pulse oximeter, the fever will be measured sublingually using a mercury thermometer. Oral tolerance will also be recorded by evaluators.

—

Secondary

Measure	Time frame
Response to treatment criteria include respiratory rate less than 24 per minute, SPO2 in room air >= 93%, absence of fever for 2 days, oral tolerance, clinical judgment of the physician. Timepoint: Response to treatment will be assessed daily, 24 hours after the first injection. Method of measurement: The number of breaths per minute will be counted by the evaluator, the blood oxygen level will be checked with a pulse oximeter, the fever will be measured sublingually using a mercury thermometer. Oral tolerance will also be recorded by evaluators.	—

Measure

Time frame

Response to treatment criteria include respiratory rate less than 24 per minute, SPO2 in room air >= 93%, absence of fever for 2 days, oral tolerance, clinical judgment of the physician. Timepoint: Response to treatment will be assessed daily, 24 hours after the first injection. Method of measurement: The number of breaths per minute will be counted by the evaluator, the blood oxygen level will be checked with a pulse oximeter, the fever will be measured sublingually using a mercury thermometer. Oral tolerance will also be recorded by evaluators.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahmood Ebrahimi

Mashhad University of Medical Sciences

EbrahmiMH@mums.ac.ir0098 51 3854450

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026